Safety and Effectiveness of Nonsteroidal Tapinarof Cream 1% Added to Ongoing Biologic Therapy for Treatment of Moderate to Severe Plaque PsoriasisJanuary 13, 2026Psoriasis
Acute Generalized Exanthematous Pustulosis Secondary to Application of Tapinarof Cream 1%October 20, 2025PsoriasisMixed Topics
Apremilast Treatment Outcomes and Adverse Events in Psoriasis Patients With HIVFebruary 5, 2025Psoriasis
The Post-PASI Era: Considering Comorbidities to Select Appropriate Systemic Psoriasis TreatmentsFebruary 3, 2025Psoriasis
Dermatologic Implications of Glycemic Control Medications for Patients with Type 2 Diabetes MellitusJanuary 3, 2025Psoriasis
Successful Treatment of Severe Dystrophic Nail Psoriasis With DeucravacitinibDecember 3, 2024Psoriasis
Eating Disorder Risk Factors and the Impact of Obesity in Patients With PsoriasisNovember 8, 2024Psoriasis
Projected 2023 Cost Reduction From Tumor Necrosis Factor α Inhibitor Biosimilars in Dermatology: A National Medicare AnalysisOctober 21, 2024Psoriasis
Considerations for the Use of Biologics in PregnancyOctober 4, 2024PsoriasisAutoimmune DiseasesAtopic Dermatitis
